Evaluation of Undifferentiated Carcinoma from an Unidentified Primary Origin (Review Articles)-Reference-Cited by-同舟云学术

Evaluation of Undifferentiated Carcinoma from an Unidentified Primary Origin (Review Articles)

Published:2023-01-01 Issue:1 Volume:1 Page:15-23
ISSN:2984-7761
Container-title:Academic International Journal of Medical Update
language:
Short-container-title:Aca. Intl. J. M. U

Author:

Zainab.Al-Ali ,Mostafa A. alwash ,Zena Mahdi Abd Ali

Abstract

Cancers with an unidentified primary site at the start of treatment are classified as cancers with an unknown original primary site. Their prevalence among cancer patients is around 5%. One of the challenges in medicine is an approach to those patients. The requirement for the early detection of malignancies or palliative care are still problem in medicine. A strategy for their treatment should be created to avoid prolong hospital stays and testing that won't improve therapy or the prognosis for those sufferers. It's crucial to identify individuals whose diseases have good prognoses since they may benefit greatly from targeted therapy, including longer survival. A targeted search for the main tumor in those patients is advised. However, for those patients who will effectively employ targeted therapies, the combination of a robust immunohistochemistry panel with novel molecular knowledge may enable the development of a specific management strategy

Publisher

Academic International Publishers

Reference44 articles.

1. Abbruzzese JL, Lenzi R, Raber MN, et al. The biology of unknown primary tumors. Semin Oncol. 1993;20:238–243.

2. Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002) Br J Cancer. 2003;89(suppl 1):S59–S66.

3. Bell CW, Pathak S, Frost P. Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. Cancer Res. 1989;49:4311–4315.

4. Bar-Eli M, Abbruzzese JL, Lee-Jackson D, et al. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res. 1993;13:1619–1623.

5. Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site.